Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA
Osteoporosis International, 10/06/09
Asche C et al. – Certain patient characteristics are predictors of physicians prescribing oral bisphosphonates. However, many patients remain untreated.
Methods- Females age 50+ years with first fracture, osteoporosis diagnosis, or BMD ≤ 2.5 (index date) were identified in Geisinger Health System electronic health record database
- Treatment defined as oral bisphosphonate prescription order (risedronate sodium, ibandronate sodium, or alendronate) ≤ 90 days post-index date
- Treatment rates assessed and a multivariate logistic model used to identify predictors of treatment separately for patients with fracture (FRAC) and with diagnosis or low BMD (ICD-9-BMD)
- FRAC group had 2,003 female patients with a mean (SD) age of 69.0 (± 11.3) years and the ICD-9-BMD group had 12,976 female patients with a mean (SD) age of 66.9 (± 10.0) years
- Within 90 days of the index date of fracture, diagnosis, or low BMD score, 188 (9.4%) patients in FRAC group and 5,395 (41.6%) in ICD-9-BMD group received treatment
- Treatment positively associated with age and oral corticosteroids and negatively associated with BMI and subsequent BMD in both groups
- Smoking currently positively associated with treatment in ICD-9-BMD group
Today in Bone Metabolism...keeping you current
Receive free subspecialty "5-minute updates" via email
Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09
Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09
A New Drug in a New Class for Postmenopausal Osteoporosis
The Female Patient, 11/11/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09
Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09
Osteoarthritis: A review of treatment options
Geriatrics, 10/21/09
Sponsor
Article Search
Sponsor


See Latest Articles


